Post-earnings recap
Reported
Wed, Jul 27, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss per share of $0.23, slightly missing expectations. The stock fell 2.45% following the announcement, reflecting investor concerns over the lack of revenue and guidance updates. The company's focus remains on its clinical trials, but the absence of specific updates may have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -7.98% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding current market conditions. They emphasized their commitment to advancing their pipeline despite challenges.
Management did not provide specific updates on ongoing clinical trials.
The company remains focused on its long-term development goals.